Our portfolio company Saphetor has signed a new partnership with Roche Turkey giving the pharma giant access to its network to facilitate scientific collaborations on new treatments for Spinal Muscular Atrophy.
Andreas Massouras, CEO of Saphetor commented: “We are very excited to partner with Roche and contribute to their important effort in developing treatments for this debilitating and often lethal disease. VarSome.com is proving an extremely valuable resource for willing clinical and research labs as well as pharmaceutical companies to collaborate on a worldwide level.”
Saphetor is the leader in diagnostic and bioinformatics solutions for clinical Next Generation Sequencing (NGS). The company developed VarSome Clinical, a clinically-certified platform for allowing fast and accurate interpretation of NGS data, which helps clinicians reach faster and more accurate diagnoses and treatment decisions for genetic conditions.